Study of Pembrolizumab and M032 (NSC 733972)
Study of Pembrolizumab and M032 (NSC 733972)
Recruiting · NCT05084430 · Registry updated 2026-01-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab and M032 (NSC 733972) | Disease Attributes, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, anaplastic astrocytoma, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, gliosarcoma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-01-22 | NCT05084430 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Alabama at Birmingham | 467 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | United States | 247 |